United European Gastroenterology Journal最新文献

{"title":"United European Gastroenterology Journal: Striving for High-Quality Clinical Guidelines.","authors":"Mohamed G Shiha, Yasuko Maeda","doi":"10.1002/ueg2.70225","DOIUrl":"10.1002/ueg2.70225","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 4","pages":"e70225"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13145333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.","authors":"M Iborra, B Botella, M D Martín-Arranz, D Ceballos, C Martínez-Pascual, A Garrido, P Varela, M Moreta, E Brunet-Mas, Y González-Lama, E Rodríguez-González, M Vicuña, J P Gisbert, I Ordás, F Argüelles-Arias, J Tosca-Cuquerella, R Vicente-Lidón, M Sierra-Ausín, I Rodríguez-Lago, D Martín-Rodríguez, J M Paredes, B Sicilia, I García de la Filia, N Jiménez, M Barreiro-de Acosta, E Betoré, I Ferrer-Bradley, L García-Alles, J M Huguet, S Castellet-Farrús, M J García, A Gutiérrez-Casbas, Á Ponferrada-Díaz, L Ramos, M Calafat, I Vera, C Suárez-Ferrer, E Fernández-Velado, S Rodríguez-Sánchez, A Mínguez, A Mancebo, J Barrio, S Lario, D R de La Cruz, Alejandro Hernández-Camba, C Rodríguez-Gutiérrez, M Chaparro, E Ricart, L Almenara-Michelena, A Balaguer, E Domènech, P Nos","doi":"10.1002/ueg2.70223","DOIUrl":"10.1002/ueg2.70223","url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real-world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real-world effectiveness, safety, and treatment persistence of UPA in patients with CD.</p><p><strong>Methods: </strong>Multicenter observational study including patients with CD who received UPA, using data from a nationwide registry. Patients were classified according to active luminal disease, extraintestinal manifestations (EIMs), or combination therapy with another biological therapy. Disease activity was assessed using the Harvey-Bradshaw Index (HBI), C-reactive protein (CRP), and fecal calprotectin (FC) at baseline and weeks 12, 24, and 52. Endoscopic outcomes were evaluated when available. Adverse events (AEs), hospitalizations, and treatment discontinuations were recorded.</p><p><strong>Results: </strong>300 patients were included, representing a highly treatment-refractory population, with 98% previously exposed to anti-TNF agents and 59% to three or more advanced therapies. In those treated for active luminal disease, corticosteroid-free clinical remission was achieved in 60%-62% of patients at weeks 12, 24 and 52. CRP normalization increased from 64% at week 12%-74% at week 52, while FC normalization improved from 48% to 64%. Patients treated for EIMs achieved high and sustained remission rates with excellent treatment persistence. Early remission at week 12 was strongly associated with sustained remission and meaningful endoscopic improvement. UPA was discontinued in 98 patients (39%). AEs were reported in 71 patients (24%).</p><p><strong>Conclusions: </strong>In this large real-world cohort, UPA demonstrated sustained clinical and biochemical effectiveness, meaningful endoscopic response, and a safety profile consistent with clinical trial data. Early response emerged as a key predictor of long-term outcomes, supporting the clinical utility of UPA.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 4","pages":"e70223"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Study on Burden, Features and Determinants of Disorders of Gut-Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study.","authors":"Giovanni Marasco, Keren Hod, Luigi Colecchia, Ami D Sperber, Olafur S Palsson, Shrikant I Bangdiwala, Giovanni Barbara","doi":"10.1002/ueg2.70226","DOIUrl":"https://doi.org/10.1002/ueg2.70226","url":null,"abstract":"<p><strong>Background and aim: </strong>Disorders of gut-brain interaction (DGBI) are highly prevalent worldwide. Although the epidemiology of DGBIs in Europe has been previously investigated, data comparing disease prevalence across European regions in relation to sociodemographic and lifestyle factors are lacking. Therefore, this study aimed to assess the prevalence, regional distribution, and associated factors of DGBI in Southern Europe, and to compare findings with other European regions.</p><p><strong>Methods: </strong>Data were drawn from the Rome Foundation Global Epidemiology Study (RFGES). A representative sample of 20,420 European adults completed a comprehensive internet-based questionnaire assessing DGBI presence, psychological distress, somatic symptoms, dietary habits, and healthcare utilization. Comparative analyses were conducted between Southern European countries and the rest of the continent (Northern, Western, and Eastern European countries). Multivariate logistic regression identified independent associated factors.</p><p><strong>Results: </strong>The prevalence of adults with at least one DGBI was significantly higher in Southern Europe than in the rest of Europe (44.0% [42.4-45.5] vs. 39.0% [38.3-39.8]; p < 0.001). Irritable bowel syndrome and functional dyspepsia were more prevalent in Southern Europe than in the rest of Europe. Similar trends were found for functional constipation and functional diarrhea. Individuals with DGBI in Southern Europe showed higher psychological distress but lower somatic symptom burden and lower work productivity and activity impairment. In multivariable models, residence in Southern Europe, female sex, younger age, higher psychological distress, greater somatic symptom burden, higher educational attainment, urban residence and more frequent healthcare utilization were independently associated with DGBI.</p><p><strong>Conclusions: </strong>Southern European populations exhibit a higher prevalence of DGBI compared with other European regions. Individuals with DGBI in Southern Europe showed higher rates of psychological distress, whereas those in the rest of Europe showed higher somatic symptom burden, greater work productivity and activity impairment. DGBI rates in Europe appear to be driven by a multifactorial interplay of demographic and psychosocial factors.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 4","pages":"e70226"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.","authors":"Jean-Frédéric Colombel, Silvio Danese, Stefan Schreiber, Bruce E Sands, Andres J Yarur, Aram Kang, Dong-Hyeon Kim, Young Nam Lee, Stephen B Hanauer","doi":"10.1002/ueg2.70205","DOIUrl":"10.1002/ueg2.70205","url":null,"abstract":"<p><strong>Background and aims: </strong>LIBERTY-CD and LIBERTY-UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti-drug antibodies (ADAs) on clinical outcomes.</p><p><strong>Methods: </strong>Patients randomized to IFX SC maintenance treatment in the LIBERTY trials were included (CD, n = 231; UC, n = 294). ADAs were tested using a highly sensitive, drug-tolerant assay. Patients were grouped by ADA occurrence and titer and evaluated for outcomes up to Week (W) 54.</p><p><strong>Results: </strong>Among patients with CD and UC, 150 (64.9%) and 187 (63.6%) were ADA-positive, respectively. No statistically significant differences were observed between the ADA-positive and ADA-negative groups in W54 efficacy (CD: clinical remission, 69.5% [95% confidence interval: 61.6-77.5] vs. 79.7% [70.2-89.2], p = 0.134; endoscopic response, 57.5% [48.9-66.1] vs. 65.2% [54.0-76.5], p = 0.359; UC: clinical remission, 49.1% [41.3-56.8] vs. 57.0% [46.5-67.4], p = 0.284), drug persistence (CD: 84.7% [79.1-90.6] vs. 85.2% [77.8-93.3]; UC: 84.5% [79.5-89.8] vs. 77.6% [70.1-85.9]), and safety (patients with ≥ 1 treatment-emergent adverse event; CD: 71.2% [64.0-78.3] vs. 74.4% [64.9-83.8]; UC: 69.5% [62.9-76.0] vs. 64.2% [55.0-73.3]), despite lower drug concentrations in ADA-positive patients at W54 (CD: 10.6 μg/mL [9.1-12.2] vs. 17.9 μg/mL [15.8-20.1]; UC: 12.2 μg/mL [10.8-13.5] vs. 21.0 μg/mL [18.4-23.6]). No significant relationship between ADA titer and efficacy or persistence was noted.</p><p><strong>Conclusions: </strong>Although ADAs affected drug levels, no significant differences by ADA occurrence were observed in W54 efficacy or safety among patients receiving IFX SC maintenance treatment. While high ADA titers were associated with lower drug levels, effectiveness was not diminished within 1 year.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifiers NCT03945019 (LIBERTY-CD) and NCT04205643 (LIBERTY-UC).</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70205"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147692612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival After Pancreatic Resection for Intraductal Papillary Mucinous Neoplasm: Supporting Selective Surgery.","authors":"Marcus Holmberg, Tomaso Dall'Olio, Mohamed Marwa, Carsten Palnaes Hansen, Dyre Berg Kleive, Gennaro Nappo, Lam Shi, Per Sandström, Dennis Björk, Parsa Hadesi, Raffaele Vincenzo De Rosa, Bodil Andersson, Daniel Ansari, Bhargava Chikkala, Letizia Todeschini, Charlotte Leseman, Job Schuitema, Yentl Lodewijks, Christopher Månsson, Spiros Delis, Frederik Berrevoet, Fabio Giannone, Sofia Xenaki, Elizabeth Pando, Claude Bertrand, Konstantinos Vasileiadis, Patrick Kirchweger, Calogero Ciulla, Claudio Luchini, Misha Luyer, Marc G Besselink, Giovanni Marchegiani, Sanjay Pandanaboyana, Bobby Tingstedt, Laurent Sulpice, Johanna Wennerblom, Bergthor Björnsson, Anita Balakrishnan, Knut Jørgen Labori, Stefan Kobbelgaard Burgdorf, Motaz Qadan, Ernesto Sparrelid, Antonio Pea, Yasmin G Hernandez-Barco, Roberto Salvia, Poya Ghorbani","doi":"10.1002/ueg2.70199","DOIUrl":"10.1002/ueg2.70199","url":null,"abstract":"<p><strong>Introduction: </strong>Resection of intraductal papillary mucinous neoplasm (IPMN) aims to prevent progression to invasive pancreatic cancer. However, the risks of pancreatic surgery and frequent findings of low-grade dysplasia (LGD) raise concerns about overtreatment. This EAHPBA-endorsed multinational study evaluated short- and long-term overall survival (OS) following preventive resection for IPMN (without pre-operative signs of cancer).</p><p><strong>Methods: </strong>Adult patients with resected IPMN showing LGD, high grade dysplasia (HGD) or T1-staged invasive carcinoma from 2008-2023 were identified from the OPTIMAL-IPMN database. Estimated OS rates at one, five and 10 years in patients undergoing preventive pancreatic resection were assessed using Kaplan-Meier analyses and predictors for mortality were evaluated using parametric survival regressions.</p><p><strong>Results: </strong>Among 2275 patients in the OPTIMAL-IPMN database, 1728 (77%) had undergone preventive pancreatic resection for IPMN. Of those were 61% resected without prior surveillance. Final pathology revealed LGD in 63%, HGD in 27% and T1a-c-staged invasive cancer in 10% (7.3% T1a-b, 2.8% T1c). Estimated 1-year OS rate was 97%. Estimated 5-year OS rates (landmark analysis at 1 year) for LGD, HGD, T1a-b, and T1c was 97%, 99%, 96% and 91% respectively. Independent predictors for long-term mortality included age ≥ 75 versus < 75 years (HR 1.97) and T1c versus LGD (HR 8.12).</p><p><strong>Conclusion: </strong>This multinational study confirms excellent survival after preventive IPMN resection but reveals many upfront resections yielding LGD with unknown survival benefit. Future studies should aim to determine which patients can be followed safely with monitoring to avoid unnecessary immediate resection.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70199"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.","authors":"Juha Taavela, Luca Elli, Gerd Bouma, Jason A Tye-Din, Detlef Schuppan, Knut E A Lundin, Michael Schumann","doi":"10.1002/ueg2.70222","DOIUrl":"https://doi.org/10.1002/ueg2.70222","url":null,"abstract":"<p><p>Celiac disease (CeD) is a chronic autoimmune enteropathy triggered by dietary gluten in genetically predisposed individuals. Currently, a gluten-free diet (GFD) is the only available treatment, being effective in improving mucosal health and symptoms. However, a considerable percentage of celiacs continue to exhibit residual mucosal damage and symptoms. In addition, dietary lapses, and social and nutritional problems pose difficulties with the GFD. Hence, there is an unmet need for new treatments in CeD, driving the development of pharmacologic interventions, with several new drugs in various stages of clinical development. These drugs target distinct steps in the immune pathology of CeD and are intended for patients who continue to experience symptoms despite trying to follow a GFD. Also, the treatment should heal the defective small intestinal mucosa, which is believed to be linked to the risk of long-term complications. This review summarizes emerging CeD therapies, covering trial progress, mechanisms, and potential clinical applications.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70222"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.","authors":"Louis Calméjane, Catherine Reenaers, Claire Gay, Aurélien Amiot, Alexandre Nuzzo, Lucine Vuitton, Calina Atanasiu, Carmen Stefanescu, Romain Altwegg, Lucas Guillo, Mélanie Serrero, Guillaume Bouguen, Maria Nachury, Guillaume Le Cosquer, Xavier Roblin, Vered Abitbol, Nassim Hammoudi, Marion Simon, Mathurin Fumery, Guillaume Savoye, Alban Benezech, Maryan Cavicchi, Maeva Charkaoui, Anthony Buisson, Bénédicte Caron, Benoît Coffin, Sophie Geyl, Félix Goutorbe, Marianne Hupé, Mathias Vidon, David Laharie, Julien Kirchgesner, Mathieu Uzzan","doi":"10.1002/ueg2.70203","DOIUrl":"10.1002/ueg2.70203","url":null,"abstract":"<p><strong>Background and aims: </strong>Vedolizumab has become the preferred first-line advanced therapy in ulcerative colitis (UC). However, the optimal second-line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second-line therapies after first-line vedolizumab.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study including UC patients from 31 centers who received infliximab (IFX), subcutaneous (SC) anti-TNFs, or ustekinumab after vedolizumab failure. The primary endpoint was steroid-free clinical remission (SFCR) at week 14. Predictors of remission were identified using multivariate logistic regression.</p><p><strong>Results: </strong>Among 196 patients, 99 received IFX, 27 anti-TNF SC, and 70 ustekinumab. At week 14, SFCR was achieved in 78 patients (39.8%): 38 (38.4%) with IFX, 8 (29.6%) with anti-TNF SC, and 32 (45.7%) with ustekinumab, with no significant difference between groups (p = 0.32). Median treatment persistence ranged from 8 to 9.2 months. Baseline corticosteroid use was associated with lower odds of SFCR (OR = 0.37, 95% CI [0.18-0.73]). Adverse events occurred in 15.8% of patients, including 12.2% serious events. Overall adverse events were less frequent with ustekinumab than with IFX (10.0% vs. 24.2%, p = 0.02), while serious events were comparable (5.7% vs. 16.1%, p = 0.08). Discontinuation due to adverse events was more frequent with IFX (12.1%) and anti-TNF SC (14.8%) than with ustekinumab (2.9%, p = 0.045 and 0.049).</p><p><strong>Conclusion: </strong>In UC patients failing vedolizumab, second-line IFX, anti-TNF SC, and ustekinumab showed similar effectiveness and persistence. Infliximab remains a robust option for rapid control in high inflammatory burden, whereas ustekinumab may be preferred for its superior safety profile in high-risk patients.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70203"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological Factors Predict Response to a Low Fermentable Oligo-, di-, Monosaccharide and Polyol Dietary Intervention in Irritable Bowel Syndrome: A Prospective Cohort Study.","authors":"Lauren P Manning, Maaike Van Den Houte, Caroline J Tuck, Lukas Van Oudenhove, Jessica R Biesiekierski","doi":"10.1002/ueg2.70204","DOIUrl":"10.1002/ueg2.70204","url":null,"abstract":"<p><strong>Background: </strong>The low fermentable oligo-, di-, monosaccharide and polyol (FODMAP) diet (LFD) effectively manages irritable bowel syndrome (IBS), but predictors of treatment response remain unknown.</p><p><strong>Objective: </strong>This study investigated whether psychological factors predict symptom improvement and quality of life (QoL) outcomes following a LFD intervention.</p><p><strong>Methods: </strong>Adults with Rome IV-defined IBS underwent a three-phase LFD over 6 months. Primary outcomes were IBS symptom severity and QoL. Validated questionnaires assessed depressive, gastrointestinal-specific anxiety (GSA), and somatic symptoms, illness perceptions, and treatment expectations. Latent class growth analysis (LCGA) and cross-lagged panel models (CLPM) were used to identify symptom trajectories and examine directional relationships between psychological factors and outcomes, respectively.</p><p><strong>Results: </strong>112 participants (89% female, median age 30 ± 17 years) completed the study. LCGA identified distinct IBS symptom severity and QoL trajectories during the LFD. Higher baseline treatment credibility and expectancy predicted favourable symptom improvements but were unrelated to membership in the QoL trajectory. Elevated GSA, psychological distress (depression, anxiety, stress), and negative illness perceptions increased the likelihood of poorer outcomes. CLPM revealed that lower GSA and higher personal control preceded subsequent symptom reductions. Higher treatment expectancy predicted improved QoL and symptom outcomes over time, while QoL improvements reduced stress and GSA.</p><p><strong>Conclusion: </strong>Lower baseline GSA anxiety and higher treatment expectations consistently predict better response to all phases of the LFD. These findings will help clinicians identify optimal candidates for dietary intervention versus alternative treatments.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70204"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Endoscopy Characteristics Between Providers With the Highest and Lowest Post Endoscopy Upper Gastrointestinal Cancer Rates in England.","authors":"Umair Kamran, Felicity Evison, Eva J A Morris, Matthew Brookes, Matt Rutter, David Beaton, Mimi McCord, Nicola J Adderley, Nigel Trudgill","doi":"10.1002/ueg2.70206","DOIUrl":"10.1002/ueg2.70206","url":null,"abstract":"<p><strong>Background: </strong>Post-endoscopy upper gastrointestinal cancer (PEUGIC) rates vary over threefold between endoscopy providers in England. To determine if variations in endoscopy characteristics contribute, providers with the lowest and highest PEUGIC rates were compared.</p><p><strong>Methods: </strong>Endoscopy providers were categorized into quartiles based on PEUGIC rates and those in the highest and lowest quartiles studied. Data for diagnostic upper gastrointestinal (UGI) endoscopy performed between January 2019 and February 2020 were extracted from the National Endoscopy Database. Multivariable regression analysis explored the endoscopy characteristics associated with the lowest PEUGIC rate providers after adjusting for patient characteristics and indications.</p><p><strong>Results: </strong>In total, 328,354 diagnostic UGI endoscopy performed by 54 providers were included. Endoscopy characteristics positively associated with the lowest PEUGIC rate providers included: training sessions (Odds Ratio 1.85 (95% CI 1.81-1.90)); intravenous sedation use (1.09 (1.07-1.11)); endoscopist average UGI endoscopy annual volume 101-200 (1.05 (1.02-1.07) and 201-300 (1.16 (1.13-1.19)). Endoscopy characteristics inversely associated with the lowest PEUGIC rate providers included: endoscopy half-day sessions with average ≥ 9 points (0.72 (0.71-0.74)); endoscopists not on nursing, specialty or trainee register (0.83 (0.81-0.85)); and biopsies during endoscopy (0.84 (0.83-0.86)). Compliance with national quality standards to biopsy high risk conditions was better in providers with the lowest PEUGIC rates.</p><p><strong>Discussion: </strong>Training sessions, more endoscopists with minimum annual endoscopy volumes > 100, more intravenous sedation, less biopsies and lower intensity endoscopy sessions were associated with the lowest PEUGIC rate providers. These findings may help guide efforts to reduce PEUGIC and improve endoscopy quality in the future.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70206"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Postoperative Prognosis to Preoperative Decision-Making in IPMN.","authors":"Man Sun, Dan Zang, Jun Chen","doi":"10.1002/ueg2.70215","DOIUrl":"10.1002/ueg2.70215","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":"14 3","pages":"e70215"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}